Track Exelixis, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Exelixis, Inc. EXEL Open Exelixis, Inc. in new tab

43.88 USD
P/E
15.78
EPS
2.78
P/B
5.33
ROE
35.53
Beta
0.42
Target Price
46.83 USD
Exelixis, Inc. logo

Exelixis, Inc.

🧾 Earnings Recap – Q3 2025

Exelixis delivered strong third-quarter results, characterized by robust revenue growth driven by the success of cabozantinib and early achievements for zanzalintinib, setting the stage for future growth.

  • Cabozantinib U.S. net product revenues rose 14% year-over-year to $543 million, maintaining its leadership in the TKI market for renal cell carcinoma (RCC).
  • Global cabozantinib revenues reached approximately $739 million, bolstered by a 50% increase in demand within the neuroendocrine tumor (NET) segment.
  • Zanzalintinib is gaining momentum with seven pivotal trials underway; recent positive results in colorectal cancer (CRC) suggest potential regulatory submissions soon.
  • The expansion of the GI sales team aims to accelerate growth in the CABINET indication, enhancing the company’s commercial footprint.
  • Exelixis is committed to a disciplined capital allocation strategy while progressing its diverse R&D pipeline for sustained long-term value creation.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 12, 2026
P/E15.78
EPS2.78
Book Value8.23
Price to Book5.33
Debt/Equity9.30
% Insiders2.204%
Growth
Revenue Growth0.06%
Earnings Growth0.84%
Estimates
Forward P/E11.17
Forward EPS3.93
Target Mean Price46.83

DCF Valuation

Tweak assumptions to recompute fair value for Exelixis, Inc. (EXEL)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Exelixis, Inc. Logo Exelixis, Inc. Analysis (EXEL)

United States Health Care Official Website Stock

Is Exelixis, Inc. a good investment? Exelixis, Inc. (EXEL) is currently trading at 43.88 USD. Market analysts have a consensus price target of 46.83 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 15.78. This valuation is generally in line with the broader market.

Earnings Schedule: Exelixis, Inc. is expected to release its next earnings report on May 12, 2026. The market consensus estimate for Forward EPS is 3.93.

Investor FAQ

Does Exelixis, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Exelixis, Inc.?

Exelixis, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 12, 2026. The company currently has a trailing EPS of 2.78.

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exchange Ticker
NMS (United States) EXEL
GER (Germany) EX9.DE
LSE (United Kingdom) 0IJO.L
FRA (Germany) EX9.F

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion